Level A· Stronger Clinical EvidenceSystematic ReviewEurope PMCOpen access

The therapeutic potential of mesenchymal stem cells-derived extracellular vesicles/exosomes on the diabetes: a systematic review study

Kouhestani M., Hosseini A.

Systematic Review on Chronic Inflammation, Immune Modulation, published in Diabetol Metab Syndr (2025) — summary generated from the PubMed abstract.

Open my reading list
Level A· Stronger Clinical EvidenceEvidence level of this study

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Systematic Review
Journal
Diabetol Metab Syndr (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41462479
PMCID
PMC12751254
DOI
10.1186/s13098-025-02020-z

Abstract (original English)

Diabetes mellitus includes a wide range of chronic metabolic disorders that result in severe hyperglycemia and other damages in diabetic patients due to impaired insulin secretion or insulin inefficiency. This study purpose was to consider of the potential therapeutic properties of MSCs-derived EVs/Exo against DM. A complete systematic search was achieved in various electronic databases (Scopus, Web of Science, PubMed and Embase) up to June 2025, following the PRISMA guidelines. A whole of 89 studies were screened based on predetermined standards for inclusion and exclusion. Eventually, the current systematic study contained 13 publications that had the criteria of inclusion. According to the findings of this study, MSCs-derived EVs/Exo reduce DM and hyperglycemia with the high ability to regulate inflammatory-immune responses and activate autophagy pathways. However, compared to the diabetic groups, treatment with MSCs-derived EVs/Exo revealed tendency towards immunomodulatory, anti-inflammatory, anti-diabetic, regeneration and neogenesis of β-islets. In other studies, have been identified that DM causes significant biochemical changes in beta cells/pancreas tissue. In addition, obvious histological changes were observed in pancreatic tissue following DM. Generally, MSCs-derived EVs/Exo administration modulated most of the histological and biochemical changes caused by diabete

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research